Sensitive Skin Syndrome in Children with Atopic Dermatitis: Pathogenesis and Management Features
Nikolay N. Murashkin,
Roman V. Epishev,
Dmitri V. Fedorov,
Alexander I. Materikin,
Eduard T. Ambarchyan,
Leonid A. Opryatin,
Alena A. Savelova,
Roman A. Ivanov,
Wasel Ahmad https://doi.org/10.15690/vsp.v18i4.2046
Abstract
The atopic dermatitis (AD) is common skin disease and has significant impact on patients and their families quality of life. In recent years the term “sensitive skin" has been used more frequently. It is separate syndrome with subjective perception (such as burning, itching, tingling, etc.) along with thickening and dryness of the skin in response to environmental factors (biotic, abiotic and anthropogenic) which normally do not cause such symptoms. This syndrome is often associated with AD. The AD and sensitive skin syndrome pathogenesis and their management are presented in the article. Efficiency and safety parameters of pimecrolimus 1% cream in children (including its appliance on sensitive skin areas) are analysed.
Supporting agencies: The article has been funded by Mylan Pharma LLC
About the Authors
Nikolay N. Murashkin
National Medical Research Center of Children's Health; Sechenov First Moscow State Medical University (Sechenov University); Central State Medical Academy of Department of Presidential Affairs
Russian Federation
Disclosure of interest:
Russian Federation
Receiving research grants from pharmaceutical companies Jansen, Eli Lilly, Novartis. Scientific consultant of Galderna, Pierre Fabre, Bayer, Leofarma, Pfizer, AbbVie, Amryt Pharma, Zeldis Pharma LLC companies
Disclosure of interest:
Absence of a reportable conflict of interests
Roman V. Epishev
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Scientific consultant of Eli Lilly, Novartis, AbbVie, Amryt Pharma companies
Dmitri V. Fedorov
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Absence of a reportable conflict of interests
Alexander I. Materikin
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Scientific consultant of Eli Lilly, Novartis, AbbVie, Amryt Pharma companies
Eduard T. Ambarchyan
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Scientific consultant of Eli Lilly, Novartis, AbbVie, Amryt Pharma, Jansen companies
Leonid A. Opryatin
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Absence of a reportable conflict of interests
Alena A. Savelova
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Absence of a reportable conflict of interests
Roman A. Ivanov
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow
Disclosure of interest:
Absence of a reportable conflict of interests
Wasel Ahmad
Berbekova Kabardino-Balkarian State University
Russian Federation
Disclosure of interest: Absence of a reportable conflict of interests
Russian Federation
Republic of Kabardino-Balkaria
Disclosure of interest: Absence of a reportable conflict of interests
References
1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann NutrMetab. 2015;66 Suppl 1:8-16. doi: 10.1159/000370220.
2. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. doi: 10.1016/j.jaad.2013.10.010.
3. Shaw TE, Currie GP Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. J Invest Dermatol. 2011;131(1):67-73. doi: 10.1038/jid.2010.251.
4. Asher MI, Weiland SK. The International Study of Asthma and Allergies in Childhood (ISAAC). ISAAC Steering Committee. Clin Exp Allergy. 1998;28 Suppl 5:52-66. doi: 10.1046/j.1365-2222.1998.028s5052.x.
5. Lee JH, Son SW, Cho SH. A comprehensive review of the treatment of atopic eczema. Allergy Asthma Immunol Res. 2016; 8(3):181-190. doi: 10.4168/aair.2016.8.3.181.
6. Bloomfield SF, Rook GA, Scott EA, et al. Time to abandon the hygiene hypothesis: new perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene. Perspect Public Health. 2016;136(4):213-224. doi: 10.1177/1757913916650225.
7. Rook GA, Martinelli R, Brunet LR. Innate immune responses to mycobacteria and the downregulation of atopic responses. Curr Opin Allergy Clin Immunol. 2003;3(5):337-342. doi: 10.1097/00130832-200310000-00003.
8. Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115-S123.
9. Reda AM, Elgendi A, Ebraheem AI, et al. A practical algorithm for topical treatment of atopic dermatitis in the Middle East emphasizing the importance of sensitive skin areas. J Dermatolog Treat. 2019;30(4):366-373. doi: 10.1080/09546634.2018.1524823.
10. Elias PM, Schmuth M. Abnormal skin barrier in the etiopatho-genesis of atopic dermatitis. Curr Opin Allergy Clin Immunol. 2009;9(5):437-446. doi: 10.1097/ACI.0b013e32832e7d36.
11. David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv Exp Med Biol. 2017;1027:21-37. doi: 10.1007/978-3-319-64804-0_3.
12. Perkin MR, Craven J, Logan K, et al. Association between domestic water hardness, chlorine, and atopic dermatitis risk in early life: a population-based cross-sectional study. J Allergy Clin Immunol. 2016;138(2):509-516. doi: 10.1016/j.jaci.2016.03.031.
13. Kim J, Han Y Ahn JH, et al. Airborne formaldehyde causes skin barrier dysfunction in atopic dermatitis. Br J Dermatol. 2016; 175(2):357-363. doi: 10.1111/bjd.14357.
14. Kim K. Influences of environmental chemicals on atopic dermatitis. Toxicol Res. 2015;31(2):89-96. doi: 10.5487/TR.2015.31.2.089.
15. Montnemery P Nihlen U, Goran Lofdahl C, et al. Prevalence of self-reported eczema in relation to living environment, socio-economic status and respiratory symptoms assessed in a questionnaire study. BMC Dermatol. 2003;3:4. doi: 10.1186/1471-5945-3-4.
16. Thyssen JP Linneberg A, Menne T, Johansen JD. The epidemiology of contact allergy in the general population — prevalence and main findings. Contact Dermatitis. 2007;57(5):287-299. doi: 10.1111/j.1600-0536.2007.01220.x.
17. Penard-Morand C, Raherison C, Charpin D, et al. Long-term exposure to close-proximity air pollution and asthma and allergies in urban children. Eur Respir J. 2010;36(1):33-40. doi: 10.1183/09031936.00116109.
18. Yoshihisa Y, Shimizu T. Metal allergy and systemic contact dermatitis: an overview. Dermatol Res Pract. 2012;2012:749561. doi: 10.1155/2012/749561.
19. Al-Shobaili HA, Ahmed AA, Alnomair N, et al. Molecular genetic of atopic dermatitis: an update. Int J Health Sci (Qassim). 2016;10(1):96-120.
20. Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14): 1483-1494. doi.org/10.1056/nejmra074081.
21. Carr WW. Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Paediatr Drugs. 2013; 15(4):303-310. doi: 10.1007/s40272-013-0013-9.
22. De Benedetto A, Agnihothri R, McGirt LY et al. Atopic dermatitis: a disease caused by innate immune defects? J Invest Dermatol. 2009;129(1):14-30. doi: 10.1038/jid.2008.259.
23. Breuer K, Wittmann M, Bosche B, et al. Severe atopic dermatitis is associated with sensitization to Staphylococcal entero-toxin B (SEB). Allergy. 2000;55(6):551-555. doi: 10.1034/j.1398-9995.2000.00432.x.
24. Boguniewicz M, Leung DY. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol. 2010;125(1):4-13; quiz 14-5. doi: 10.1016/j.jaci.2009.11.027.
25. Duarte I, Silveira JE, Hafner MF, et al. Sensitive skin: review of an ascending concept. An Bras Dermatol. 2017;92(4):521-525. doi: 10.1590/abd1806-4841.201756111.
26. Misery L, Stander S, Szepietowski JC, et al. Definition of sensitive skin: an expert position paper from the special interest group on sensitive skin of the International Forum for the Study of Itch. Acta Derm Venereol. 2017;97(1):4-6. doi: 10.2340/00015555-2397.
27. Talagas M, Misery L. Role of keratinocytes in sensitive skin. Front Med (Lausanne). 2019;6:108. doi: 10.3389/fmed.2019.00108.
28. Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol. 2012;26(8):1045-1060. doi: 10.1111/j.1468-3083.2012.04635.x.
29. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi: 10.1016/j.jaad.2014.03.023.
30. Kempers S, Boguniewicz M, Carter E, et al. A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis. J Am Acad Dermatol. 2004;51: 515-525. doi: 10.1016/j.jaad.2004.01.051.
31. Luger T, Boguniewicz M, Carr W, et al. Pimecrolimus in atopic dermatitis: consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol. 2015;26(4):306-315. doi: 10.1111/pai.12331.
32. Luger T, De Raeve L, Gelmetti C, et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur J Dermatol. 2013;23(6):758-766. doi: 10.1684/ejd.2013.2169.
33. Sigurgeirsson B, Boznanski A, Todd G, et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015;135(4):597-606. doi: 10.1542/peds.2014-1990.
34. Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children. J Eur Acad Dermatol Venereol. 2018;32(6):850-878. doi: 10.1111/jdv.14888.
35. Fowler J, Johnson A, Chen M, Abrams K. Improvement in pruritus in children with atopic dermatitis using pimecrolimus cream 1%. Cutis. 2007;79(1):65-72.
36. Aschoff R, Schmitt J, Knuschke P, et al. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecroli-mus 1% cream in uninvolved forehead skin of patients with atopic dermatitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832-836. doi: 10.1111/j.1600-0625.2011.01335.x.
37. Gschwind HP Waldmeier F, Zollinger M, et al. Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro. Eur J Pharm Sci. 2008;33(1):9-19. doi: 10.1016/j.ejps.2007.09.004.
38. Billich A, Aschauer H, Aszodi A, Stuetz A. Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm. 2004;269(1):29-35. doi: 10.1016/j.ijpharm.2003.07.013.
39. Luger TA, Lahfa M, Folster-Holst R, et al. Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat. 2004;15(3):169-178. doi: 10.1080/09546630410033781.
40. Lubbe J, Friedlander SF, Cribier B, et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. Am J Clin Dermatol. 2006;7(2):121-131. doi: 10.2165/00128071-200607020-00005.
41. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics. 2002;110(1 Pt 1):e2. doi: 10.1542/peds.110.1.e2.
42. Valdman-Grinshpoun Y, Ben-Amitai D, Zvulunov A. Barrierrestoring therapies in atopic dermatitis: current approaches and future perspectives. Dermatol Res Pract. 2012;2012:923134. doi: 10.1155/2012/923134.
43. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol. 2003;17(5):493-503. doi: 10.1046/j.1468-3083.2003.00692.x.
44. Arellano FM, Wentworth CE, Arana A, et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol. 2007;127(4):808-816. doi: 10.1038/sj.jid.5700622.
Review
For citations:
Murashkin N.N., Epishev R.V., Fedorov D.V., Materikin A.I., Ambarchyan E.T., Opryatin L.A., Savelova A.A., Ivanov R.A., Ahmad W. Sensitive Skin Syndrome in Children with Atopic Dermatitis: Pathogenesis and Management Features. Current Pediatrics. 2019;18(4):285-293. (In Russ.) https://doi.org/10.15690/vsp.v18i4.2046
Views:
1145
Email this article 
